Tag Archives: DTV

Top Stocks To Invest In 2018

April 7, 2017: Here are four stocks trading with relatively heavy volume among 60 equities making new 52-week lows in Friday’s session. On the NYSE, decliners led advancers by about 8 to 7 and on the Nasdaq advancers and decliners traded evenly, 1,400 to 1,409.

DryShips Inc. (NASDAQ: DRYS) dropped about 30% Friday to post a new 52-week low of $0.72 after closing at $1.03 on Thursday. Volume was about 15% above the daily average of around 31 million. The company said late Thursday that it will execute a 1-for-4 reverse stock split effective April 11. This marks the fifth reverse split in the firm’s stock in 13 months.

Valeant Pharmaceuticals International Inc. (NYSE: VRX) dropped about 2% Friday to post a new 52-week low of $9.44 after closing Thursday at $9.63. The stock’s 52-week high is $38.50. Volume of nearly 15 million shares was about 25% below the daily average of around 19.5 million. The stock is on track to post a gain of around 0.5% for the day following an offer from Fresenius SE to acquire Akorn. Barron’s suggests that investors must believe there’s a buyer for anything, so why not Valeant?

Top Stocks To Invest In 2018: Merck & Company, Inc.(MRK)

Advisors’ Opinion:

  • [By Paul Ausick]

    The DJIA stock posting the largest daily percentage gain ahead of the close Tuesday was Merck & Co. Inc. (NYSE: MRK) which traded up 6.19% at $62.29. The stock’s 52-week range is $53.63 to $66.80. Volume was more than three times the daily average of around 12.2million shares. The company’s lung cancer treatment drug met goals in a Phase 3 trial.

  • [By Arie Goren]

    Sales of Gileads blockbuster hepatitis C drugs Harvoni, Sovaldi and the new drug Epclusa, which was launched in the United States and Europe in June and July 2016, fell 16.6% compared to the previous quarter and 30.7% year-over-year to $3,325 million. The decline in Gileads HCV revenue has been mostly due to lower patient starts for Harvoni and lower revenues per patient, and the deep discount the company had to offer to maintain its high market share due to the competition from AbbVie’s (NYSE:ABBV)HCV drug Viekira, and Merck’s (NYSE:MRK)HCV drug Zepatier.

  • [By Ben Levisohn]

    Short story is, growth products are slowing and large net price increases are appearing increasingly unsustainable, even if the government doesn’t intervene. The innovation cycle appears to be in a waning period and, so far, large-caps with boatloads of cash seem to be hesitant to act. 2017 should have some excitement. We may finally see a successful registrational study in Alzheimer’s disease (Axovant Sciences’ (AXON) intepirdine or Merck’s (MRK) verubecestat), CAR T will finally get to plead its case, and we may find out once and for all if those ‘transformational’ PCSK9s are just that…

Top Stocks To Invest In 2018: DIRECTV(DTV)

Advisors’ Opinion:

  • [By Christopher Freeburn]

    Service disruptions on DirecTV’s (DTV) website temporarily interfered with subscribers’ ability to stream National Football League (NFL) games online for the last two Sundays.

Top Stocks To Invest In 2018: Akebia Therapeutics, Inc.(AKBA)

Advisors’ Opinion:

  • [By Alex McGuire]

    As a service to our readers, the following list provides the 10 top pharmaceutical stocks to watch this month (May 2017), including the biggest gainers from April…

    Pharmaceutical Stock Current Share Price April 2017 Gain
    Cleveland BioLabs Inc. (Nasdaq: CBLI) $3.62 +120.6%
    Nexvet Biopharma Plc. (Nasdaq: NVET) $6.61 +69.7%
    Motif Bio Plc. (Nasdaq ADR: MTFB) $10.10 +68.2%
    Axovant Sciences Ltd. (NYSE: AXON) $24.43 +62.3%
    Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC) $5.49 +46.7%
    Conatus Pharmaceuticals Inc. (Nasdaq: CNAT) $8.67 +44.9%
    Akebia Therapeutics Inc. (Nasdaq: AKBA) $13.07 +43.3%
    Akorn Inc. (Nasdaq: AKRX) $33.28 +38.9%
    Rockwell Medical Inc. (Nasdaq: RMTI) $8.78 +37.4%
    Akari Therapeutics Plc. (Nasdaq ADR: AKTX) $15.02 +35.4%

    The best-performing pharma stock of the month – Cleveland BioLabs Inc. – surged 120.6% to $3.53 a share by April 28. That crushed both the Nasdaq Biotech Index’s 1.5% gain and the Dow Jones’ 1.3% rise over the same period.

  • [By Todd Campbell]

    After inking an expanded deal withOtsuka Pharmaceutical on its midstage anemia drug, shares ofAkebia Therapeutics (NASDAQ:AKBA)skyrocketed 33.4% today.

  • [By Lisa Levin]

    Shares of Akebia Therapeutics Inc (NASDAQ: AKBA) got a boost, shooting up 39 percent to $13.04. Akebia Therapeutics and Otsuka disclosed that they have expanded relationship with collaboration to develop and commercialize Vadadustat in Europe, China and other territories.

  • [By Keith Speights]

    You might not have heard too much about Akebia Therapeutics (NASDAQ:AKBA), BioMarin Pharmaceutical (NASDAQ:BMRN), and Idera Pharmaceuticals (NASDAQ:IDRA). These are three biotech stocks that you could be overlooking — but deserve your attention. Here’s why.


    For the details of Novo A’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Novo+A

    These are the top 5 holdings of Novo AInogen Inc (INGN) – 3,549,320 shares, 59.83% of the total portfolio. Acceleron Pharma Inc (XLRN) – 1,553,937 shares, 9.34% of the total portfolio. Dermira Inc (DERM) – 1,984,364 shares, 7.81% of the total portfolio. Shares added by 3.27%Corvus Pharmaceuticals Inc (CRVS) – 3,244,046 shares, 4.76% of the total portfolio. Akebia Therapeutics Inc (AKBA) – 2,225,000 shares, 4